| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Celgene Corporation (NASDAQ: CELG)
CELG Technical Analysis
5
| As on 31st Oct 2017 CELG Share Price closed @ 100.97 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 125.52 & Strong Sell for SHORT-TERM with Stoploss of 134.40 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CELG Share Price
| Open | 101.93 | Change | Price | % |
| High | 102.50 | 1 Day | 0.00 | 0.00 |
| Low | 98.83 | 1 Week | 0.00 | 0.00 |
| Close | 100.97 | 1 Month | -35.49 | -26.01 |
| Volume | 12725323 | 1 Year | -18.48 | -15.47 |
| 52 Week High 147.17 | 52 Week Low 94.55 | ||||
NASDAQ USA Most Active Stocks
| YHOO | 52.58 | 0.00% |
| FNFG | 10.18 | -0.20% |
| DELL | 13.86 | 0.22% |
| RFMD | 16.59 | -2.07% |
| MU | 44.31 | 6.39% |
| RIMM | 13.03 | 0.39% |
| BBEP | 0.12 | 0.00% |
| GTAT | 0.44 | 0.00% |
| SUSQ | 14.20 | -0.77% |
| INTC | 45.49 | 2.52% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CELG Daily Charts |
CELG Intraday Charts |
Whats New @ Bazaartrend |
CELG Free Analysis |
|
|
CELG Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 104.37 |
| RESISTANCE | 102.97 |
| SUPPORT | 98.97 |
| SUPPORT | 97.57 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
CELG Target for Month January
| 4th UP TARGET | 202.37 |
| 3rd UP TARGET | 169.85 |
| 2nd UP TARGET | 149.75 |
| 1st UP TARGET | 129.65 |
| 1st DOWN TARGET | 72.29 |
| 2nd DOWN TARGET | 52.19 |
| 3rd DOWN TARGET | 32.09 |
| 4th DOWN TARGET | -0.43 |
CELG Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
CELG Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Celgene Corporation ( NASDAQ USA Symbol : CELG )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CELG Business Profile
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
